🏛️ Verified NIH Record • Updated 2026-05-12
A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus (NCT04963296)
A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study To Evaluate The Efficacy And Safety of Obinutuzumab in Patients With Systemic Lupus Erythematosus
🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: Hoffmann-La Roche
🩺 Plain-English Summary (8th-Grade Level)
This parallel-group, double-blind, placebo-controlled study will evaluate the efficacy and safety of obinutuzumab versus placebo in participants with active, autoantibody-positive systemic lupus erythematosus (SLE) who are treated with standard-of-care therapy.
Who can join: Review the eligibility criteria below.
Location: Pinnacle Research Group — Anniston, Alabama
Age range: 18 Years to 75 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (64 Sites)
Showing the first 25 of 64 sites.
- Pinnacle Research Group — Anniston, Alabama
- Unity Health - White County Medical Center- Rheumatology — Searcy, Arkansas
- Providence Medical Foundation — Fullerton, California
- Arthritis & Rheumatism — Aventura, Florida
- Great Lakes Center of Rheumatology — Lansing, Michigan
- Clinical Research Institute of Michigan, LLC — Troy, Michigan
- Northwell Health Division of Rheumatology — Great Neck, New York
- Columbia University Medical Center — New York, New York
- Joint & Muscle Research Institute — Charlotte, North Carolina
- The Ohio State University Wexner Medical Center — Columbus, Ohio
- Paramount Medical Research & Consulting, LLC — Middleburg Heights, Ohio
- Precision Comprehensive Clinical Research Solutions — Colleyville, Texas
- Texas Arthritis Center — El Paso, Texas
- Prolato Clinical Research Center — Houston, Texas
- Organizacion Medica de Investigacion — Buenos Aires,
- DOM Centro de Reumatología — Buenos Aires,
- Centro de Investigaciones Médicas Tucuman — San Miguel,
- Ser Servicos Especializados Em Reumatologia — Salvador, Estado de Bahia
- Hospital das Clinicas - UFMG — Belo Horizonte, Minas Gerais
- Santa Casa de Misericordia — Belo Horizonte, Minas Gerais
- Centro Mineiro de Pesquisa - CMIP — Juiz de Fora, Minas Gerais
- Centro de Estudos em Terapias Inovadoras ? CETI — Curtiba, Paraná
- Hospital das Clinicas - FMUSP Ribeirao Preto — Ribeirão Preto, São Paulo
- Centro Multidisciplinar de Estudos Clínicos - CEMEC*X* — São Bernardo do Campo, São Paulo
- Revmatologicky Ustav — Prague,
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Systemic Lupus Erythematosus
- A Study of Obexelimab in Patients With Systemic Lupus Erythematosus — Peoria, Arizona
- REACH (Restore Energy, Activity Can Help) Lupus Study — Boston, Massachusetts
- Subcutaneous Anifrolumab in Adult Patients With Systemic Lupus Erythematosus — Birmingham, Alabama
- A Treatment Effectiveness Study Among SLE Patients Receiving Anifrolumab in Routine Clinical Practice — Innsbruck, Tyrol
- A Study to Assess Effectiveness and Safety of Deucravacitinib Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE) — Birmingham, Alabama
Explore by condition: All Systemic Lupus Erythematosus clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Review the official NIH record below to find the coordinating site.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.